Evidence map›Paper›PMID 42220799›Full record

ArticleCureus2026

Chylous Ascites After Robotic Retroperitoneal Lymph Node Dissection Resolved After 80 Days of Conservative Management: A Case Report.

Markus Angerer, Niclas Flechtenmacher, Christian Wülfing, Klaus-Peter Dieckmann

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Markus AngererDepartment of Urology, Asklepios Klinik Altona, Hamburg, DEU.
Niclas FlechtenmacherDepartment of Urology, Asklepios Klinik Altona, Hamburg, DEU.
Christian WülfingDepartment of Urology, Asklepios Klinik Altona, Hamburg, DEU.
Klaus-Peter DieckmannDepartment of Urology, Asklepios Klinik Altona, Hamburg, DEU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chylous ascites (CA) is the accumulation of chylous lymphatic fluid within the abdominal cavity, usually resulting from laceration of the cisterna chyli or one of its major tributaries during retroperitoneal surgery. If left untreated, CA may become life-threatening. Current treatment recommendations favor a stepwise approach, beginning with conservative measures, followed by percutaneous interventions and, in refractory cases, surgical shunting procedures. Conservative management typically consists of dietary restriction of long-chain triglycerides, escalation to total parenteral nutrition (TPN), and adjunctive pharmacotherapy with somatostatin analogues. In most reported cases, these measures result in cessation of chylous leakage within several days. We report a case of CA after robotic-assisted retroperitoneal lymph node dissection (RPLND) in a 35-year-old male with testicular seminoma. Conservative management included paracentesis with drain insertion, TPN, and pharmacotherapy with octreotide. Ascitic fluid analysis confirmed CA with a triglyceride level of 420 mg/dL. Because chylous leakage did not cease after 60 days of hospital-based management, home-based TPN via a central venous port was initiated. Chylous leakage finally resolved after 80 days of conservative treatment. One year later, the patient remained well and had experienced no recurrence of either CA or seminoma. This case demonstrates that conservative treatment of CA may occasionally require a prolonged course and considerable patience from both the patient and the treating team.

Indexed as

chylous ascitesparenteral nutritionretroperitoneal lymph node dissectionrobotic surgeryseminomatesticular cancer

Identifiers

PMID42220799
PMCPMC13216839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.